Amgen is a global biopharmaceutical company focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our portfolio, along with our pipeline, is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We are relentless in pursuing breakthroughs that boldly change the lives of the communities we serve. Discover more about our medicines in rheumatology, including the first and only biologic treatment for uncontrolled gout, and research for new therapeutic targets in gout and systemic sclerosis at www.amgen.com.

Arthrosi Therapeutics is a late-stage biotechnology company developing a potentially best-in-class, highly efficacious and selective, once daily, next generation, oral URAT1 inhibitor to reduce serum urate, flares, and dissolve tophi in gout and tophaceous gout patients.  Arthrosi is currently conducting two pivotal Phase 3 pivotal trials in gout and tophaceous gout patients.

Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. Headquartered in San Diego, California, and co-founded by Catalys Pacific and Novo Holdings, Crystalys brings together a world-class team with deep expertise in gout drug development, dedicated to delivering more effective options for people living with gout. The company’s lead candidate, dotinurad, is a next-generation, once daily oral, URAT1 inhibitor in clinical development as a second-line therapy aimed to reduce uric acid, gout flares and tophi. Dotinurad was invented by Fuji Yakuhin and has obtained regulatory approval in Japan, China, Philippines and Thailand. With best-in-class potential for both safety and efficacy, dotinurad is supported by clinical data from multiple Asian markets where it is approved. Crystalys is advancing dotinurad in global Phase 3 trials toward regulatory approval and commercial launch. For more information, visit www.crystalystx.com/ and follow us on X and LinkedIn.

At Sobi, we are transforming the lives of people affected by rare diseases. As a specialized biopharmaceutical company, we provide sustainable medicines to innovative therapies in the areas of hematology, immunology and specialty care. We bring something rare to rare diseases – a rare expertise and a strength in access that allows us to be a partner in care for those with high unmet needs. Sobi headquarters are located in Stockholm, Sweden.